Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLFS BioLife Solutions	$21.42 +1.8%	$22.22	$19.10 ▼ $29.55	$1.01B	1.79	418,126 shs	489,084 shs
MDXG MiMedx Group	$6.72 +0.1%	$6.49	$5.47 ▼ $10.14	$991.08M	1.76	698,121 shs	1.17 million shs
NYXH Nyxoah	$8.28 +3.9%	$7.55	$5.55 ▼ $11.87	$271.46M	1.62	76,413 shs	30,026 shs
TNDM Tandem Diabetes Care	$15.36 -2.5%	$19.78	$14.87 ▼ $47.60	$1.05B	1.48	1.50 million shs	1.76 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLFS BioLife Solutions	+1.81%	-5.72%	-1.47%	-2.24%	-4.84%
MDXG MiMedx Group	+0.15%	-0.88%	+14.87%	+0.67%	-9.92%
NYXH Nyxoah	+3.89%	+6.98%	+6.98%	+37.31%	-10.00%
TNDM Tandem Diabetes Care	-2.48%	-5.01%	-23.47%	-8.90%	-66.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLFS BioLife Solutions	2.4004 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6
MDXG MiMedx Group	3.7361 of 5 stars	3.5	2.0	0.0	3.3	3.3	1.9
NYXH Nyxoah	2.5614 of 5 stars	3.5	3.0	0.0	2.7	0.8	0.6
TNDM Tandem Diabetes Care	4.3364 of 5 stars	4.2	1.0	4.9	4.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLFS BioLife Solutions	3.00	Buy	$31.17	45.50% Upside
MDXG MiMedx Group	3.00	Buy	$11.50	71.13% Upside
NYXH Nyxoah	3.00	Buy	$14.50	75.12% Upside
TNDM Tandem Diabetes Care	2.33	Hold	$32.71	112.98% Upside

Current Analyst Ratings Breakdown

Latest NYXH, BLFS, TNDM, and MDXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00
7/9/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$24.00 ➝ $14.00
6/16/2025	TNDM Tandem Diabetes Care	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$24.00
5/22/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $24.00
5/13/2025	BLFS BioLife Solutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/1/2025	TNDM Tandem Diabetes Care	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $59.00
5/1/2025	TNDM Tandem Diabetes Care	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $31.00
5/1/2025	TNDM Tandem Diabetes Care	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$22.00 ➝ $20.00
5/1/2025	TNDM Tandem Diabetes Care	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$36.00 ➝ $30.00
5/1/2025	TNDM Tandem Diabetes Care	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$33.00 ➝ $24.00
4/21/2025	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLFS BioLife Solutions	$82.25M	12.46	$0.12 per share	171.74	$7.52 per share	2.85
MDXG MiMedx Group	$348.88M	2.84	$0.33 per share	20.25	$1.31 per share	5.13
NYXH Nyxoah	$4.89M	57.67	N/A	N/A	$3.60 per share	2.30
TNDM Tandem Diabetes Care	$940.20M	1.09	N/A	N/A	$4.01 per share	3.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLFS BioLife Solutions	-$20.18M	-$0.29	N/A	N/A	N/A	-11.81%	-0.66%	-0.58%	8/14/2025 (Estimated)
MDXG MiMedx Group	$42.42M	$0.27	24.89	21.00	N/A	11.40%	22.70%	16.77%	7/30/2025 (Estimated)
NYXH Nyxoah	-$64.10M	-$2.13	N/A	N/A	N/A	-1,571.39%	-63.37%	-46.67%	8/5/2025 (Estimated)
TNDM Tandem Diabetes Care	-$96.03M	-$2.78	N/A	N/A	N/A	-18.71%	-57.33%	-13.48%	8/6/2025 (Confirmed)

Latest NYXH, BLFS, TNDM, and MDXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BLFS BioLife Solutions	-$0.02	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	TNDM Tandem Diabetes Care	-$0.40	N/A	N/A	N/A	$238.39 million	N/A
8/5/2025	Q2 2025	NYXH Nyxoah	-$0.60	N/A	N/A	N/A	$1.33 million	N/A
7/30/2025	Q2 2025	MDXG MiMedx Group	$0.06	N/A	N/A	N/A	$90.79 million	N/A
5/14/2025	Q1 2025	NYXH Nyxoah	-$0.49	-$0.63	-$0.14	-$0.63	$1.64 million	$1.12 million
5/8/2025	Q1 2025	BLFS BioLife Solutions	-$0.03	$0.04	+$0.07	-$0.01	$22.22 million	$23.94 million
4/30/2025	Q1 2025	MDXG MiMedx Group	$0.06	$0.06	N/A	$0.05	$86.32 million	$88.21 million
4/30/2025	Q1 2025	TNDM Tandem Diabetes Care	-$0.60	-$0.67	-$0.07	-$1.97	$220.19 million	$234.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NYXH Nyxoah	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLFS BioLife Solutions	0.01	4.73	3.74
MDXG MiMedx Group	0.09	4.70	4.13
NYXH Nyxoah	0.22	3.59	3.35
TNDM Tandem Diabetes Care	1.99	2.30	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLFS BioLife Solutions	93.24%
MDXG MiMedx Group	79.15%
NYXH Nyxoah	N/A
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
BLFS BioLife Solutions	2.20%
MDXG MiMedx Group	1.70%
NYXH Nyxoah	17.11%
TNDM Tandem Diabetes Care	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLFS BioLife Solutions	440	47.83 million	46.78 million	Optionable
MDXG MiMedx Group	870	147.70 million	145.19 million	Optionable
NYXH Nyxoah	110	34.06 million	28.23 million	Not Optionable
TNDM Tandem Diabetes Care	2,650	66.61 million	65.34 million	Optionable

NYXH, BLFS, TNDM, and MDXG Headlines

Recent News About These Companies

FY2025 Earnings Estimate for TNDM Issued By Leerink Partnrs

July 18 at 3:01 AM | americanbankingnews.com

Tandem Diabetes Care's SWOT analysis: stock faces headwinds amid market shifts

July 17 at 10:55 PM | investing.com

What is Leerink Partnrs' Estimate for TNDM FY2025 Earnings?

July 16 at 6:46 AM | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Hits New 52-Week Low - Here's What Happened

July 15 at 2:44 PM | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

Earnings Forecast & History for Tandem Diabetes Care Inc (TNDM) | Price ...

July 12, 2025 | investing.com

Citigroup Reaffirms Sell Rating for Tandem Diabetes Care (NASDAQ:TNDM)

July 11, 2025 | americanbankingnews.com

Tandem Diabetes stock falls after Citi downgrades to Sell on competition concerns

July 9, 2025 | au.investing.com

Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes

July 9, 2025 | finance.yahoo.com

Tandem Diabetes Shares Drop Following Citi Downgrade Over Rising Competition

July 9, 2025 | msn.com

Why Tandem Diabetes (TNDM) Shares Are Sliding Today

July 9, 2025 | msn.com

Tandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month Low - Here's Why

July 9, 2025 | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Given "Sell" Rating at Citigroup

July 9, 2025 | marketbeat.com

Further weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83%

July 7, 2025 | finance.yahoo.com

Mirae Asset Global Investments Co. Ltd. Sells 265,554 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

July 6, 2025 | marketbeat.com

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Morningstar

July 2, 2025 | morningstar.comM

RSI Alert: Tandem Diabetes Care (TNDM) Now Oversold

July 2, 2025 | nasdaq.com

TNDM - Tandem Diabetes Care Inc Key Metrics - Morningstar

July 1, 2025 | morningstar.comM

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 1, 2025 | businesswire.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - Here's Why

July 1, 2025 | marketbeat.com

TNDM - Tandem Diabetes Care Inc Financials - Morningstar

June 27, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

NYXH, BLFS, TNDM, and MDXG Company Descriptions

BioLife Solutions NASDAQ:BLFS

$21.42 +0.38 (+1.81%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$21.43 +0.01 (+0.05%)

As of 08:55 AM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

MiMedx Group NASDAQ:MDXG

$6.72 +0.01 (+0.15%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$6.72 0.00 (0.00%)

As of 09:15 AM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nyxoah NASDAQ:NYXH

$8.28 +0.31 (+3.89%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$8.30 +0.02 (+0.29%)

As of 08:29 AM Eastern

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Tandem Diabetes Care NASDAQ:TNDM

$15.36 -0.39 (-2.48%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$15.65 +0.29 (+1.89%)

As of 09:16 AM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time